Results 161 to 170 of about 10,250,216 (364)
Widening the spectrum of players affected by genetic changes in Wilms tumor relapse
iScienceSummary: Few studies investigated the genetics of relapsed Wilms tumor (WT), suggesting the SIX1 gene, the microRNA processing genes, and the MYCN network as possibly involved in a relevant percentage of relapses. We investigated 28 relapsing WT patients Sara Ciceri, Alessia Bertolotti, Annalisa Serra, Giovanna Gattuso, Luna Boschetti, Maria Capasso, Cecilia Cecchi, Stefania Sorrentino, Paola Quarello, Chiara Maura Ciniselli, Paolo Verderio, Loris De Cecco, Giacomo Manenti, Francesca Diomedi Camassei, Paola Collini, Filippo Spreafico, Daniela Perotti +16 moredoaj +1 more sourcePICALM::MLLT10 translocated leukemia
FEBS Letters, EarlyView.This comprehensive review of PICALM::MLLT10 translocated acute leukemia provides an in‐depth review of the structure and function of CALM, AF10, and the fusion oncoprotein (1). The multifaceted molecular mechanisms of oncogenesis, including nucleocytoplasmic shuttling (2), epigenetic modifications (3), and disruption of endocytosis (4), are then ...John M. Cullen, Antonia C. Nakatsugawa, Natalie Barton, Henry Haines, Gary S. Stein, Janet L. Stein, Daniel S. Wechsler, Jessica L. Heath +7 morewiley +1 more sourceCell wall target fragment discovery using a low‐cost, minimal fragment library
FEBS Letters, EarlyView.LoCoFrag100 is a fragment library made up of 100 different compounds. Similarity between the fragments is minimized and 10 different fragments are mixed into a single cocktail, which is soaked to protein crystals. These crystals are analysed by X‐ray crystallography, revealing the binding modes of the bound fragment ligands.Kaizhou Yan, Mathew Stanley, Olawale Raimi, Andrew T. Ferenbach, Helge C Dorfmueller, Daan M. F. van Aalten +5 morewiley +1 more sourceBiological, clinical and population relevance of 95 loci for blood lipids. [PDF]
, 2010 Plasma concentrations of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides are among the most important risk factors for coronary artery disease (CAD) and are targets for therapeutic ...Aulchenko, Yurii S, Barbalic, Maja, Bis, Joshua C, Chambers, John, Chasman, Daniel I, Croteau-Chonka, Damien C, Edmondson, Andrew C, Feitosa, Mary F, Fouchier, Sigrid W, Guo, Xiuqing, Hua Zhao, Jing, Isaacs, Aaron, Jin Go, Min, Jin Kim, Young, Johansen, Christopher T, Johnson, Toby, Kim, Kyunga, Koseki, Masahiro, Lamina, Claudia, Lange, Leslie A, Lee, Jong-Young, Li, Mingyao, Li, Xiaohui, Luan, Jian'an, McCarthy, Mark I, McPherson, Ruth, Meitinger, Thomas, Melander, Olle, Montgomery, Grant W, Musunuru, Kiran, Nickerson, Deborah A, Nieminen, Markku S, O'Donnell, Christopher J, Oostra, Ben A, Orho-Melander, Marju, Pare, Guillaume, Park, Taesung, Parker, Alex N, Pattaro, Cristian, Pedersen, Nancy L, Peloso, Gina M, Penninx, Brenda WJH, Perola, Markus, Pichler, Irene, Pirruccello, James P, Pramstaller, Peter P, Psaty, Bruce M, Ricketts, Sally L, Rieder, Mark, Ripatti, Samuli, Roberts, Robert, Rose, Lynda M, Rudan, Igor, Ruokonen, Aimo, Sabatti, Chiara, Saharinen, Juha, Salomaa, Veikko, Sanna, Serena, Schlessinger, David, Scott, James, Scuteri, Angelo, Shin Cho, Yoon, Sijbrands, Eric JG, Silander, Kaisa, Sim, Xueling, Sinisalo, Juha, Smit, Johannes H, Smith, Albert V, Smith, Joshua D, Song, Kijoung, Soranzo, Nicole, Spector, Tim D, Stringham, Heather M, Stylianou, Ioannis M, Surakka, Ida, Tanaka, Toshiko, Teslovich, Tanya M, Thompson, John R, Thorleifsson, Gudmar, Tuomilehto, Jaakko, Twee-Hee Ong, Rick, Uda, Manuela, Uitterlinden, Andre G, Vitart, Veronique, Voight, Benjamin F, Vollenweider, Peter, Waeber, Gérard, Wareham, Nicholas J, Waterworth, Dawn M, Whitfield, John B, Wichmann, H-Erich, Willemsen, Gonneke, Willer, Cristen J, Wilson, James F, Witteman, Jacqueline CM, Wright, Alan F, Yuan, Xin, Zee, Robert YL, Zhang, Weihua, Ziegler, Andreas +99 morecore PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer
Molecular Oncology, EarlyView.PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer +21 morewiley +1 more sourceExome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)
Genetics in Medicine, 2021 Kandamurugu Manickam, M. McClain, L. Demmer, Sawona Biswas, H. Kearney, J. Malinowski, L. Massingham, Danny Miller, T. Yu, F. Hisama +9 moresemanticscholar +1 more source
